Innate Pharma (IPHA) Non-Current Debt (2017 - 2025)

Innate Pharma (IPHA) has reported Non-Current Debt for 9 consecutive years, with $15.7 million the latest figure, recorded in Q4 2025.

• Quarterly Non-Current Debt fell 38.21% year-over-year to $15.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.7 million (down 38.21% YoY) and the FY2025 annual result came in at $25.7 million, down 27.17% from the prior year.
• Non-Current Debt declined to $15.7 million in Q4 2025 per IPHA's latest filing, from $20.6 million in the prior quarter.
• Over the last five years, Non-Current Debt for IPHA reached as high as $45.7 million in Q4 2022 and fell as low as $15.4 million in Q4 2021.
• A 5-year average of $28.2 million and a median of $27.8 million in 2024 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2021 — Non-Current Debt tumbled 99.9% — and 2022, when it surged 197.33%.
• Year by year, Non-Current Debt stood at $15.4 million in 2021, then jumped by 197.33% to $45.7 million in 2022, then decreased by 22.89% to $35.2 million in 2023, then slipped by 28.01% to $25.4 million in 2024, then slumped by 38.21% to $15.7 million in 2025.
• According to Business Quant data, Non-Current Debt over the past three periods registered $15.7 million, $20.6 million, and $25.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.